Calliditas: Obtains positive feedback regarding study design
Research Note
2019-09-03
08:24
Calliditas this morning announced that it has received acceptance of a design change of the Part B of the pivotal Nefigard study, which will have a positive effect on the timeline and cost related to this confirmatory part of the study. The news does not affect the timeline for top-line data for the trial, which based on positive data may form the basis for an accelerated approval. We continue to expect top-line data in H2 2020.
LS
Ludvig Svensson
Disclosures and disclaimers